Stefan Kachala, MD, Thoracic Surgery, New Britain, CT, Hartford Hospital


Thoracic Surgery New Britain, CT

Adult General Thoracic Surgery, Minimally Invasive Thoracic Surgery, Thoracic Surgical Oncology

Thoracic Surgeon Hartford Healthcare Medical Group

Dr. Kachala is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Kachala's full profile

Already have an account?

Education & Training

  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationFELLOWSHIP
  • New York Presbyterian Hospital - Cornell Campus
    New York Presbyterian Hospital - Cornell CampusRESIDENCY
  • Rutgers Robert Wood Johnson Medical School
    Rutgers Robert Wood Johnson Medical SchoolMEDICAL_SCHOOL
  • Rutgers College, Rutgers UniversityOTHER_TRAINING

Certifications & Licensure

  • CT State Medical License
    CT State Medical License 2017 - 2021
  • OH State Medical License
    OH State Medical License 2014 - 2018
  • American Board of Surgery Surgery
  • American Board of Thoracic Surgery Thoracic and Cardiac Surgery

Awards, Honors, & Recognition

  • Finalist C. Walton Lillehei Resident Forum (AATS), 2013
  • Resident Research Scholarship American College of Surgeon, 2010
  • Alpha Omega Alpha, Medical Honor Society RWJMS-UMDNJ, 2007
  • Join now to see all

Publications & Presentations


Journal Articles

  • Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-free and Overall Survival in Early-Stage Lung Adenocarcinoma  
    Kachala S, Bograd AJ, Villena-Vargas J, Suzuki K, Servais EL, Kadota K, Chou JF, Sima CS, Vertes E, Rusch VW, Travis WD, Sadelain M, Adusumilli PS, Clinical Cancer Research, 1/15/2014
  • Lung Transplantation for Multifocal Lung Adenocarcinoma  
    Kachala SS and Murthy SC, Thoracic Surgery Clinics, 1/1/2014
  • Adusumilli PS High-SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: Supportive evidence to reclassify pleomorphic as non-...  
    Kadota K, Kachala SS, Nitadori JI, Suzuki K, Dunphy MP, Sima CS, Travis WD, Rusch VW, Journal of Thoracic Oncology, 1/1/2012
  • Join now to see all

Books/Book Chapters


  • Mesothelin Expression Promotes An Aggressive Phenotype Of Non-Small Cell Lung Cancer (NSCLC).
    Vertes EL, Kachala S, Servais E, Rodriguez L, Rusch W, Sadelain M, Adusumilli P, Oncology-Tumor Biology Forum of the 6th Annual Academic Surgical Congress (ASC), Huntington Beach, CA, 1/1/2011
  • Mesothelin expression promotes invasive phenotype and matrix metalloproteinase secretion in pleural mesothelioma.
    Servais E, Colovos C, Kachala S, Rodriguez L, Kadota K, Rusch V, Sadelain M, Adusumilli P, Basic Science Forum at the 10th International Conference of the International Mesothelioma Interest Group, Kyoto, Japan, 1/31/2010
  • Ghinassi B, Ferro L, Kachala S, Riviere I, Sadelain M, Migliaccio AF, Basic Science Forum of the 52nd Annual Meeting of the American Society of Hematology, Orlando, FL, 1/4/2010
  • Join now to see all


  • Beneficial Role of Antigen Commensalism in Mesothelin-Targeted T-cell Therapy for Lung Adenocarcinoma. 
  • Mesothelin Overexpression Imparts an Aggressive Phenotype and Decreases Recurrence-Free Survival in Early Stage Lung Adenocarcinoma. 
    Minneapolis, MN - 1/4/2013
  • Mesothelin is a commonly expressed tumor marker in lung adenocarcinoma (LAC) that imparts an aggressive phenotype-a candidate molecular target. 
    Amsterdam, Netherlands - 1/3/2011

Professional Memberships

Hospital Affiliations